Healthy Soch
Seven Years of Data Confirm Both Minimally Invasive and Open-Heart Valve Replacement Deliver Lasting Results. What This Means for India’s Growing Heart Disease Burden
Landmark global study published in The New England Journal of Medicine offers critical guidance as India faces a rising tide of valve disease in younger and older patients alike
India
healthysoch
New Delhi, March 05, 2026:
India is quietly facing a dual cardiac crisis. On one hand, rheumatic heart disease, largely preventable yet still widespread, continues to damage heart valves in young adults
across rural and semi-urban India. On the other, an ageing urban population is increasingly developing degenerative aortic stenosis, the same type of valve disease that affects millions in the West.
Together, these two conditions are placing an enormous and growing burden on India’s cardiac care system. Against this backdrop, a landmark seven-year study published in The New England Journal of Medicine—one of the world’s most respected medical journals—offers findings that are directly relevant to how India approaches valve disease treatment today.
The study tracked 1,000 patients with severe, symptomatic aortic stenosis over seven years,
comparing two treatment approaches: TAVR (Transcatheter Aortic Valve Replacement), a minimally invasive procedure where the valve is replaced through a small tube without open-chest surgery, and traditional open-heart surgical valve replacement. The average patient age was 73 years, and all patients were considered low surgical risk, a profile increasingly seen in Indian cardiac centres.
The Key Finding:
Both Approaches Work Equally Well Over Seven Years. At the seven-year mark, outcomes were comparable across both groups. The combined rate of death, stroke, or heart-related rehospitalisation was 34.6% in the TAVR group and 37.2% in the surgery group, a difference that was not statistically significant. More strikingly, over 73% of patients in both groups were alive and free of valve failure seven years after their procedure.
In plain terms: whether a patient received a minimally invasive valve replacement or open-heart surgery, their long-term outcomes were similar.
Specific findings at seven years:
Death from any cause: 19.5% (TAVR) vs 16.8% (surgery).
Stroke: 8.5% vs 8.1%.
Rehospitalisation: 20.6% vs 23.5%.
Valve failure: 6.9% vs 7.3%.
Why This Matters Specifically for India :
India is at an inflection point in cardiac care. Current estimates suggest RHD affects 1.5–2 per 1,000 people across all ages, with a prevalence of 0.5-6 per 1,000 people, across all ages. More than 2 million people are living with this condition. At the same time, studies from major Indian tertiary centers have reported a significant and rising proportion of degenerative calcific aortic stenosis, the aging valve disease that this study directly addresses in patients presenting before the age of 60.
This means Indian patients are often younger at the time of their first valve intervention than their Western counterparts. A 50-year-old receiving a valve replacement today may live another 30 or 40 years. The question of which valve approach to choose — and how to plan for the decades that follow — is therefore far more consequential in the Indian context than in populations where the average patient is in their late 70s.
Seven-year durability data, like those published in this study, are precisely the kind of evidence Indian cardiologists and their patients need to make informed, long-term decisions.
In India, we are no longer just managing valve disease, we are planning for a patient’s entire cardiac future, said Dr. Praveen Chandra, Chairman-Interventional Cardiology, D.M. (Cardiology) , M.D. (General Medicine) , M.B.B.S, Medanta Gurugram . "This data gives us meaningful confidence that both approaches can deliver sustained benefit. But it also reinforces that the first valve decision needs to be made carefully, with the next 20 to 30 years in mind, not just the procedure itself.
A Nuanced Picture:
Not All Outcomes Were Identical. While the headline results were comparable, the study revealed important differences worth noting. New-onset atrial fibrillation, an irregular heart rhythm that increases stroke risk, occurred more
frequently after open-heart surgery (43.5%) than after the minimally invasive approach (17.7%). Pacemaker implantation was more common after TAVR (17.3% vs 12.8%).
These nuances matter for the Indian patient population, where access to long-term anticoagulation monitoring and follow-up care can vary significantly between urban hospitals and rural or semi- urban settings.
The Road Ahead:
Lifetime Planning, Not Just a Single Procedure. Perhaps the most important message from this study — one that resonates deeply in the Indian context — is that valve replacement is the beginning of a long journey, not its endpoint.
As TAVR gains rapid adoption across India and becomes a more affordable option, the question of what happens 10, 15, or 20 years after the first procedure becomes urgent. . The study confirms that both treatment approaches show comparable durability at seven years. A final 10-year report is expected, which will be watched closely by the global cardiac community.
For now, the evidence supports what leading Indian cardiologists have been advocating: every patient with severe aortic stenosis deserves a thorough evaluation by a multidisciplinary heart team, a treatment plan tailored to their age, anatomy, lifestyle, and long-term goals, and a structured follow-up plan that treats valve replacement not as a one-time event but as the start of lifelong cardiac care.
Nearly three-quarters of patients in this study were alive with mild or no heart failure symptoms at seven years, a powerful reminder of what timely, well-planned intervention can achieve. For the millions of Indians living with undetected or undertreated valve disease, that outcome is not just a statistic. It is a future worth fighting for.
